KYORIN Pharmaceutical (4569) · InitiativeFirst stated
In-Licensing a Domestic Distribution Agreement for Sirturo
First written in FY2026. . Latest entry: FY2026.
2entries
1years
1from disclosures
How it moved
Same theme, other companies
Introduction of a domestic sales agreement for Satyro with Johnson & JohnsonA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026First statedAnnual report
「Sirturo; Johnson & Johnson; United States; 2026; through 31 December 2031 from the date of execution, with possible extension by agreement.」
An in-licensed distribution agreement for Sirturo was signed with Johnson & Johnson in 2026, with a term through 31 December 2031. - 2026-03-25First statedBusiness Alliance
「We hereby announce that, on 25 March 2026, we entered into an exclusive distribution agreement in Japan with Johnson & Johnson (legal entity for its prescription pharmaceutical business in Japan: Janssen Pharmaceutical K.K.; head office: Chiyoda-ku, Tokyo; Representative Director and President: Chris Rieger; hereinafter “J&J”) for SIRTURO® tablets 100 mg, an antituberculosis agent (generic name: bedaquiline fumarate; hereinafter the “Product”).」
The company newly announced the execution of an exclusive distribution agreement for SIRTURO in Japan and the start of sole promotional activities from June 2026. Following approval of an additional indication for pulmonary MAC disease, it plans to receive product supplies from J&J and distribute the Product exclusively.